🇺🇸 FDA
Patent

US 11926825

Compounds and methods for reducing ATXN2 expression

granted A61KA61K47/02A61K47/46

Quick answer

US patent 11926825 (Compounds and methods for reducing ATXN2 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K47/02, A61K47/46